SAN DIEGO, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 3,320,000 shares of its common stock at a price to the public of $30.75 per share. The gross proceeds to Receptos from this offering are expected to be approximately $102.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an aggregate of 498,000 additional shares of common stock. The offering is expected to close on or about January 14, 2014, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
